<scp>l</scp>‐Arginine treatment for asymmetric fetal growth restriction

Xiao, Xu; Li, L.P.

doi:10.1016/j.ijgo.2004.09.017

Cited by 90 publications

(63 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gene expression and protein tissue content of arginase II (enzyme that degrades arginine to ornithine) were found to be higher in preeclamptic villi than in normotensive pregnancy [12]. Arginase II over-expression is seen in lower L-arginine concentration which causes increase in peroxynitrite (isoform of nitric oxide synthase).…”

Section: Discussionmentioning

confidence: 99%

Role of l-Arginine in Oligohydramnios

Soni

Seeru

Patel

et al. 2016

J Obstet Gynecol India

View full text Add to dashboard Cite

Background Oligohydramnios is a known obstetric complication which is associated with operative interferences and perinatal morbidity and mortality. L-arginine is a precursor of nitric oxide and may play a role in local vasodilatation. Administration of L-arginine has been suggested to improve amniotic fluid index (AFI) in oligohydramnios. Aims and Objectives To study the effect of L-arginine in optimizing fetal outcome in cases of oligohydramnios. Materials and Methods A retrospective study was conducted at Dr L H Hiranandani hospital consisting of 100 antenatal patients diagnosed with oligohydramnios [AFI \ 8 cm] remote from term. Patients were evaluated for all antenatal risk factors and were started on L-arginine

show abstract

Section: Discussionmentioning

confidence: 99%

Role of l-Arginine in Oligohydramnios

Soni

Seeru

Patel

et al. 2016

J Obstet Gynecol India

View full text Add to dashboard Cite

show abstract

“…35,36 Maternal nitrite/nitrate plasma levels have been found to be decreased in pregnancies with intrauterine growth restriction. 37,38 Treatment with the NO donor L-arginine was able to increase birth weight in those cases. 38,39 A small study reported that fetuses of women with at least one rare allele of the NOS3 VNTR 4a/b polymorphism weigh less at birth.…”

Section: Discussionmentioning

confidence: 99%

“…37,38 Treatment with the NO donor L-arginine was able to increase birth weight in those cases. 38,39 A small study reported that fetuses of women with at least one rare allele of the NOS3 VNTR 4a/b polymorphism weigh less at birth. 40 According to the results from our large study population, the analysed maternal NOS3 polymorphisms do not influence fetal growth and birth weight.…”

Section: Discussionmentioning

confidence: 99%

Impact of maternal endothelial nitric oxide synthase gene polymorphisms on blood pressure, protein excretion and fetal outcome in pregnancy

Hocher

Hügle

et al. 2008

J Hum Hypertens

View full text Add to dashboard Cite

A genetic association study was conducted to assess whether genetically determined alterations of the nitric oxide system are associated with clinical markers of preeclampsia. A large number of Caucasian women were consecutively included after delivery and genotyped for the endothelial nitric oxide synthase gene (NOS3) polymorphisms G894T, T789C (n ¼ 1502) and intron 4a/b (n ¼ 2186). There are no significant differences in mean blood pressure (BP), protein excretion or new-onset peripheral oedema between any of the genotypes over the course of pregnancy. Neither particular haplotypes nor the combined presence of any two alleles is associated with those markers of pre-eclampsia. The maternal polymorphisms do not seem to influence fetal growth, birth weight or the incidence of congenital malformations. We demonstrate in a large Caucasian population that maternal polymorphisms of the NOS3 gene are not related to clinical markers of pre-eclampsia. The functional relevance of the NOS3 variants alone does not seem to be strong enough to affect BP regulation during pregnancy.

show abstract

“…For example, during late (week 33) gestation, daily intravenous infusion of arginine (20 g/day) for 7 days to women with unknown causes of IUGR increased birth weight at term (week 39) by 6.4% (Xiao and Li, 2005). Moreover, results of a more recent study indicated that administration of Arg to women with an IUGR fetus was effective in reducing placental apoptosis and improving fetal growth and development (Shen and Hua, 2011).…”

Section: Argininementioning

confidence: 99%

Pregnancy recognition signals in mammals: the roles of interferons and estrogens

Bazer

Johnson

2017

Anim Reprod

View full text Add to dashboard Cite

Reproduction is a highly complex biological process requiring a dialogue between the developing conceptus (embryo-fetus and associated placental membranes) and maternal uterus which must be established during the peri-implantation period for pregnancy recognition signaling and regulation of gene expression by uterine epithelial and stromal cells. The uterus provide a microenvironment in which molecules secreted by uterine epithelia or transported into the uterine lumen represent histotroph or the secretome required for growth and development of the conceptus and receptivity of the uterus to implantation by the conceptus. Pregnancy recognition signaling as related to sustaining the functional lifespan of the corpora lutea (CL) which produce progesterone; the hormone of pregnancy essential for uterine functions that support implantation and placentation required for successful outcomes of pregnancy. It is within the periimplantation period that most embryonic deaths occur in mammals due to deficiencies attributed to uterine functions or failure of the conceptus to develop appropriately, signal pregnancy recognition and/or undergo implantation and placentation. The endocrine status of the pregnant female and her nutritional status are critical for successful establishment and maintenance of pregnancy. The challenge is to understand the complexity of key mechanisms that are characteristic of successful reproduction and to use that knowledge to enhance fertility and reproductive health of animals including nonhuman primates. It is important to translate knowledge gained from studies of animals to address issues of fertility and reproductive health in humans.

show abstract

l‐Arginine treatment for asymmetric fetal growth restriction

Abstract: A deficiency in nitric oxide may play an important role in the development of asymmetric fetal growth restriction. L-Arginine can be used to increase maternal NO2-/NO3- levels and newborn birth weight.

Cited by 90 publications

References 7 publications

Role of l-Arginine in Oligohydramnios

Role of l-Arginine in Oligohydramnios

Impact of maternal endothelial nitric oxide synthase gene polymorphisms on blood pressure, protein excretion and fetal outcome in pregnancy

Pregnancy recognition signals in mammals: the roles of interferons and estrogens

Contact Info

Product

Resources

About